Summit Therapeutics shares traded higher Tuesday as investors repriced the company’s regulatory setup around ivonescimab after the FDA accepted Summit’s first Biologics License Application and set a Nov. 14, 2026 PDUFA date for a decision in EGFR-mutated non-small cell lung cancer. With no obvious new press release driving headlines today, the move appears driven by renewed catalyst positioning and speculative flow into the name.

SMMT has unusually high short interest for a large-cap biotech, creating conditions where modest incremental buying can move the stock meaningfully. As of Mar. 31, 2026, roughly 34.6 million shares were sold short, equating to about 29.5% of the public float, a setup that can magnify rallies when momentum turns positive.

The core near-term debate is how the FDA will weigh the submitted package for ivonescimab ahead of the Nov. 14, 2026 action date, and whether additional clinical disclosures in 2026 further support differentiated efficacy and safety. Investors are also watching the breadth of Summit’s combination strategy, including its January 2026 clinical trial collaboration with GSK to study ivonescimab with a B7-H3 antibody-drug conjugate, with trials expected to start in mid-2026.